Pfizer | PFE - Debt


Pfizer reported $63.73B in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Abbott USD 34.05B 20.19B Mar/2026
ALKERMES USD 1.58B 1.51B Mar/2026
Amgen USD 54.6B 17M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
Bayer EUR 36.45B 2.93B Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Drreddys Laboratories INR 77.34B 9.61B Mar/2026
Eli Lilly USD 42.5B 3.6M Dec/2025
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Glaxosmithkline GBP 19.06B 1.31B Mar/2026
J&J USD 54.99B 7.05B Mar/2026
Medtronic USD 28.07B 1.03B Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
Novartis USD 47B 11.62B Mar/2026
Novartis USD 47B 14.98B Mar/2026
Pacira USD 367.66M 4.53M Mar/2026
Perrigo USD 3.64B 4.5M Dec/2025
Pfizer USD 63.73B 231M Mar/2026
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 1.08B 38.27M Dec/2025
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sanofi EUR 20.33B 1.43B Dec/2025
Sanofi EUR 20.02B 1.73B Mar/2026
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026
Zoetis USD 9.24B 1.96B Dec/2025